Iparomlimab (QL1604)
Monoclonal antibody
Evidence outlook · registrational
Registrational readout pending
No completed mid-stage readout is on record. Registrational readout expected around 2029-07-15. The sponsor reported topline results of a Phase 2 study on 2023-12-06 (Qilu reports the pivotal Phase 2 result of iparomlimab in dMMR/MSI-H solid tumors (ORR 45.8%)); that is not the registrational readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
No investor-visible indication is recorded for this drug.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (1)
What this study did
Phase 2/3 (2)
What this study did
What this study did
Phase 2 (31)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (3)
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Phase 4 (1)
What this study did
Early phase / not applicable (1)
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
Other PD-1 drugs
Cemiplimab, Dostarlimab, Nivolumab, Opdivo Qvantig, Pembrolizumab and 21 more. Compare all 27 PD-1 drugs
This mechanism is crowded: 26 other tracked programmes target it, 10 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Iparomlimab (QL1604): this drug | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Cemiplimab | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2) NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7) | |
| Dostarlimab | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03602859: Progression Free Survival (PFS) (Up to approximately 316 weeks): Paclitaxel + Carboplatin + Dostarlimab Pbo +/- Bev, Then Niraparib+Dostarlimab Pbo +/- Bev (Arm2) 19.19 Months (95% CI 16.59 to 20.99) | Paclitaxel + Carboplatin + Dostarlimab +/- Bev, Then Niraparib+Dostarlimab +/- Bev (Arm3) 20.63 Months (95% CI 19.22 to 22.77) NCT04655976: Overall Survival (OS) (Arm A Versus Arm C) (Up to approximately 234 weeks): Cobolimab + Dostarlimab + Docetaxel (Arm A) 11.9 Months (95% CI 10.6 to 14.2) vs Docetaxel (Arm C) 11.3 Months (95% CI 9.5 to 13.9) missed | |
| Nivolumab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT02388906: Recurrence-free Survival (RFS) (up to 36 months): Nivolumab 3 mg/kg 52.37 Months | Ipilimumab 10 mg/kg 24.08 Months (95% CI 16.56 to 35.09) NCT03036098: Sub-study (cisplatin-eligible), nivolumab + gemcitabine-cisplatin vs gemcitabine-cisplatin: PFS HR 0.72 (95% CI 0.59 to 0.88), p=0.0018; OS median 21.7 vs 18.9 months, HR 0.78 (95% CI 0.63 to 0.96), p=0.0171. Primary study, nivolumab + ipilimumab vs chemotherapy: OS in PD-L1 >=1% 16.3 vs 14.4 months, primary not met per BMS; OS in cisplatin-ineligible 19.1 vs 13.2 months, HR 0.79 (95% CI 0.64 to 0.97), posted p=0.0032 (CT.gov posted results). | |
| Opdivo Qvantig | Approved(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Pembrolizumab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT03914612: PFS with pembrolizumab plus paclitaxel/carboplatin vs placebo plus chemotherapy: dMMR cohort 12-month PFS 74% vs 38% (HR 0.30, 95% CI 0.19 to 0.48, P<0.001); pMMR cohort median 13.1 vs 8.7 months (HR 0.54, 95% CI 0.41 to 0.71, P<0.001) (NRG-GY018, NEJM 2023). NCT04003636: Overall Survival (OS) (Up to approximately 38 months): Arm A: Pembrolizumab + Chemotherapy 12.7 Months (95% CI 11.5 to 13.6) | Arm B: Placebo + Chemotherapy 10.9 Months (95% CI 9.9 to 11.6) | |
| Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex) | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | Featured results are non-efficacy only | |
| Penpulimab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT03866993: Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. | |
| Retifanlimab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT04205812: Overall Survival (up to 39.1 months): Retifanlimab + Chemotherapy 18.1 months (95% CI 16.2 to 21) vs Placebo + Chemotherapy 13.4 months (95% CI 11 to 16.7) | |
| Tislelizumab | Approved(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed NCT03412773: Overall survival, tislelizumab vs sorafenib: median 15.9 vs 14.1 months, hazard ratio 0.85 (95.003% CI 0.712 to 1.019); upper bound below the 1.08 non-inferiority margin, so non-inferior; superiority not shown (one-sided p=0.0398 vs boundary 0.0223) (CT.gov posted results). | |
| Toripalimab | Approved(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT04158440: Primary, investigator-assessed EFS in the stage III population (interim analysis, n=404): median not estimable vs 15.1 months, toripalimab + chemotherapy vs placebo + chemotherapy; HR 0.40 (95% CI 0.28 to 0.57); P<.001, met. Primary, BIPR-assessed MPR rate in the stage III population: 48.5% vs 8.4% (difference 40.2%, 95% CI 32.2% to 48.1%; P<.001), met. Primaries, EFS and MPR rate in the stage II-III population (final analysis): the sponsor states both met the pre-defined efficacy boundary; figures not yet published, met. NCT04085276: PFS in the intent-to-treat population (this trial's stated primary analysis population): median 8.4 vs 6.9 months, HR 0.77, P=0.0445, toripalimab+nab-paclitaxel vs placebo+nab-paclitaxel. Also reported for the PD-L1-positive population: median 8.4 vs 5.6 months, HR 0.653, 95% CI 0.470-0.906, P=0.0102 | |
| Abp 234 | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| BAT3306 | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary | |
| Camrelizumab | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT04613674: Pathological complete response: 56.8% (126/222) camrelizumab+chemotherapy vs 44.7% (98/219) placebo+chemotherapy; rate difference 12.2% (95% CI 3.3%-21.2%), 1-sided P=.004 NCT03134872: Primary 1, BICR-assessed PFS in all treated randomized patients (interim analysis): median 11.3 vs 8.3 months, camrelizumab plus carboplatin and pemetrexed vs carboplatin and pemetrexed; HR 0.60 (95% CI 0.45 to 0.79); one-sided p=0.0001, met. Primary 2, BICR-assessed PFS in PD-L1-positive patients: no confirmatory test reported. | |
| Cetrelimab | Phase 3(overall) | Monoclonal antibody | PD-1 | Weak signal | Featured results are safety only | |
| CT-P51 | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Enlonstobart | Phase 3(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| MB12 | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | No reviewed efficacy summary | |
| Serplulimab | Phase 3(overall) | Monoclonal antibody | PD-1 | Reliable signal | NCT04033354: At the final analysis, serplulimab plus chemotherapy significantly improved median OS compared to placebo plus chemotherapy (HR 0.73, 95% CI 0.58-0.93; p=0.010); at the second interim analysis, the PFS benefit was maintained in the serplulimab-chemotherapy group (HR 0.53, 95% CI 0.42-0.67). NCT03952403: Final analysis in nonsquamous NSCLC: median overall survival reached 26.8 months for Hetronifly (serplulimab) plus chemotherapy compared with 20.3 months for chemotherapy alone, a 34% reduction in the risk of death (HR=0.66, 95% CI: 0.52-0.83, P<0.001); median PFS was 11.0 months in Group B versus 5.7 months in the chemotherapy-only arm. No statistical difference was observed for Group A compared to Group B (HR=1.12, p=0.3628). | |
| Sintilimab | Phase 3(overall) | Monoclonal antibody | PD-1 | Partial signal | NCT03150875: Overall survival: sintilimab median 11.79 vs docetaxel 8.25 months (HR 0.74, 95% CI 0.56 to 0.96, P=0.025) (ORIENT-3, Cancer Commun 2022). NCT03607539: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Independent Radiographic Review Committee (IRRC) (Trough Database Cutoff Date of 15-Nov-2019 (Up to approximately 16 months)): Sintilimab Combination 8.9 Months (95% CI 7.1 to 11.3) vs Placebo Combination 5 Months (95% CI 4.8 to 6.2) | |
| Budigalimab | Phase 2/3(overall) | Monoclonal antibody | PD-1 | not yet graded | NCT03000257: Phase 1 dose-escalation confirmed tolerability and linear PK; RP2D established | |
| Sasanlimab | Phase 2/3(overall) | Monoclonal antibody | PD-1 | Partial signal | Featured results are dose-finding only | |
| Balstilimab | Phase 2(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| SHR-3045 | Phase 2(overall) | Undisclosed | PD-1 | not yet graded | No reviewed efficacy summary | |
| IOV-4001 | Phase 1/2(overall) | Cell therapy | PD-1 | not yet graded | No reviewed efficacy summary | |
| OSE-279 | Phase 1/2(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary | |
| Bmab1700 | Phase 1(overall) | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary |
Upcoming events
(32 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Iparomlimab (QL1604) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
November 2026 (1)
What to watch
December 2026 (1)
What to watch
2027 (8)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
May 2027 (1)
What to watch
July 2027 (1)
What to watch
August 2027 (2)
What to watch
What to watch
November 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (15)
January 2028 (2)
March 2028 (1)
What to watch
June 2028 (1)
What to watch
July 2028 (4)
What to watch
What to watch
What to watch
What to watch
August 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (5)
What to watch
What to watch
What to watch
What to watch
What to watch
2029 (5)
April 2029 (1)
What to watch
June 2029 (1)
What to watch
July 2029 (1)
What to watch
2030 (2)
March 2030 (1)
What to watch
June 2030 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent